Show simple item record

dc.contributor.authorMartin, Virginie
dc.contributor.authorVouldoukis, Ioannis
dc.contributor.authorMoreno, Javier 
dc.contributor.authorMcGahie, David
dc.contributor.authorGueguen, Sylvie
dc.contributor.authorCuisinier, Anne-Marie
dc.identifier.citationVet Res. 2014 Jun 25;45:69.es_ES
dc.description.abstractControl of canine leishmaniasis is an important objective for the benefit of dogs living in or visiting endemic areas and for public health because of the zoonotic nature of this disease. Resistance or susceptibility to developing canine leishmaniasis after exposure to Leishmania infantum is primarily determined by the ability of the immune system to develop an appropriate Th1-dominated specific response to the parasite. For this reason there is a need for effective canine vaccines that can decrease the number of dogs developing progressive infections. In this study, we followed the impact of the LiESP/QA-21 canine vaccine (composed of excreted-secreted proteins of L. infantum and the QA-21 saponin adjuvant), recently launched commercially in Europe, on selected humoral and cellular immune parameters following an infectious intravenous challenge with L. infantum promastigotes administered one year after the primary vaccine course. We also followed parasitological parameters to determine the parasitological status of the challenged dogs. In contrast to controls, vaccinated dogs retained significantly stronger cell-mediated immune responses against the parasite despite a virulent challenge and had significantly lower mean parasite burdens at the end of the study, associated with a lower probability of developing active infections. These results confirm that the immune responses generated by vaccination with LiESP/QA-21 are still effective against an intravenous challenge one year after the primary vaccine course.es_ES
dc.description.sponsorshipThis study was funded by Virbac, which commercialises the vaccine that was the subject of this research. Several of the authors are employees of Virbac. Virbac played a direct role in the study design, data collection and analysis, decision to publish and preparation of the manuscript.es_ES
dc.publisherBioMed Central (BMC) es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshBone Marrow es_ES
dc.subject.meshDog Diseases es_ES
dc.subject.meshDogs es_ES
dc.subject.meshFemale es_ES
dc.subject.meshImmunization Schedule es_ES
dc.subject.meshLeishmania infantum es_ES
dc.subject.meshMale es_ES
dc.subject.meshParasite Load es_ES
dc.subject.meshTh1 Cells es_ES
dc.subject.meshTime Factors es_ES
dc.subject.meshAdaptive Immunity es_ES
dc.subject.meshLeishmaniasis Vaccines es_ES
dc.titleThe protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year lateres_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderVirbac (France) 
dc.identifier.journalVeterinary researches_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional